Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more
Vicore Pharma Holding AB (publ) (VICO) - Net Assets
Latest net assets as of December 2025: Skr1.10 Billion SEK
Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) has net assets worth Skr1.10 Billion SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.22 Billion) and total liabilities (Skr124.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.10 Billion |
| % of Total Assets | 89.82% |
| Annual Growth Rate | 126.69% |
| 5-Year Change | 185.79% |
| 10-Year Change | 1349.08% |
| Growth Volatility | 40579.59 |
Vicore Pharma Holding AB (publ) - Net Assets Trend (2012–2025)
This chart illustrates how Vicore Pharma Holding AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vicore Pharma Holding AB (publ) (2012–2025)
The table below shows the annual net assets of Vicore Pharma Holding AB (publ) from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.10 Billion | -3.00% |
| 2024-12-31 | Skr1.13 Billion | +147.99% |
| 2023-12-31 | Skr455.39 Million | +57.53% |
| 2022-12-31 | Skr289.08 Million | -24.58% |
| 2021-12-31 | Skr383.32 Million | +8.12% |
| 2020-12-31 | Skr354.51 Million | +10.24% |
| 2019-12-31 | Skr321.60 Million | +12.67% |
| 2018-12-31 | Skr285.44 Million | +152.67% |
| 2017-12-31 | Skr112.97 Million | +49.43% |
| 2016-12-31 | Skr75.60 Million | -7.73% |
| 2015-12-31 | Skr81.93 Million | +52.58% |
| 2014-12-31 | Skr53.70 Million | +34.21% |
| 2013-12-31 | Skr40.01 Million | +152326.85% |
| 2012-12-31 | Skr26.25K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vicore Pharma Holding AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr140.76 Million | 12.85% |
| Other Components | Skr954.70 Million | 87.15% |
| Total Equity | Skr1.10 Billion | 100.00% |
Vicore Pharma Holding AB (publ) Competitors by Market Cap
The table below lists competitors of Vicore Pharma Holding AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hampidjan hf
IC:HAMP
|
$182.38 Million |
|
PHC Holdings Corporation
PINK:PHCCF
|
$182.38 Million |
|
Korea Electronic Power Industrial Development Co Ltd
KO:130660
|
$182.42 Million |
|
Blue Foundry Bancorp
NASDAQ:BLFY
|
$182.43 Million |
|
Seche Environnem.
PA:SCHP
|
$182.20 Million |
|
InnovAge Holding Corp
NASDAQ:INNV
|
$182.19 Million |
|
Humacyte Inc
NASDAQ:HUMA
|
$182.16 Million |
|
Global Indemnity Group, LLC Class A Common Stock
NASDAQ:GBLI
|
$182.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vicore Pharma Holding AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,129,329,000 to 1,095,462,000, a change of -33,867,000 (-3.0%).
- Net loss of 477,474,000 reduced equity.
- New share issuances of 455,098,000 increased equity.
- Other factors decreased equity by 11,491,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-477.47 Million | -43.59% |
| Share Issuances | Skr455.10 Million | +41.54% |
| Other Changes | Skr-11.49 Million | -1.05% |
| Total Change | Skr- | -3.00% |
Book Value vs Market Value Analysis
This analysis compares Vicore Pharma Holding AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.19x to 2.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.77 | Skr10.10 | x |
| 2013-12-31 | Skr3.09 | Skr10.10 | x |
| 2014-12-31 | Skr4.15 | Skr10.10 | x |
| 2015-12-31 | Skr5.82 | Skr10.10 | x |
| 2016-12-31 | Skr5.39 | Skr10.10 | x |
| 2017-12-31 | Skr6.65 | Skr10.10 | x |
| 2018-12-31 | Skr12.47 | Skr10.10 | x |
| 2019-12-31 | Skr7.47 | Skr10.10 | x |
| 2020-12-31 | Skr6.53 | Skr10.10 | x |
| 2021-12-31 | Skr5.50 | Skr10.10 | x |
| 2022-12-31 | Skr4.00 | Skr10.10 | x |
| 2023-12-31 | Skr4.72 | Skr10.10 | x |
| 2024-12-31 | Skr5.01 | Skr10.10 | x |
| 2025-12-31 | Skr4.57 | Skr10.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vicore Pharma Holding AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12509.14%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-43.59%) is below the historical average (-28.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -12.03% | -95.29% | 0.09x | 1.46x | Skr-5.78K |
| 2013 | -4.01% | -48.50% | 0.06x | 1.27x | Skr-5.60 Million |
| 2014 | 25.49% | 871.23% | 0.03x | 1.11x | Skr8.32 Million |
| 2015 | -5.58% | -544.05% | 0.01x | 1.09x | Skr-12.76 Million |
| 2016 | -8.80% | -780.75% | 0.01x | 1.08x | Skr-14.21 Million |
| 2017 | -11.38% | -1379.29% | 0.01x | 1.06x | Skr-24.15 Million |
| 2018 | -7.60% | -4267.91% | 0.00x | 1.06x | Skr-50.22 Million |
| 2019 | -28.94% | 0.00% | 0.00x | 1.06x | Skr-125.24 Million |
| 2020 | -41.43% | 0.00% | 0.00x | 1.15x | Skr-182.31 Million |
| 2021 | -77.35% | 0.00% | 0.00x | 1.18x | Skr-334.81 Million |
| 2022 | -99.77% | 0.00% | 0.00x | 1.17x | Skr-317.33 Million |
| 2023 | -68.28% | 0.00% | 0.00x | 1.09x | Skr-356.48 Million |
| 2024 | -14.93% | -154.22% | 0.09x | 1.07x | Skr-281.57 Million |
| 2025 | -43.59% | -12509.14% | 0.00x | 1.11x | Skr-587.02 Million |
Industry Comparison
This section compares Vicore Pharma Holding AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vicore Pharma Holding AB (publ) (VICO) | Skr1.10 Billion | -12.03% | 0.11x | $182.21 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |